生态融合：从数据孤岛到决策闭环 新浪财经最独特的优势在于构建了"资讯-分析-交易"的完整闭环。它创新性地整合微博财经大V观点， 在每一条行情变动或政策发布时，社区的专业解读与情绪反馈同步呈现，形成动态知识网络。当某只股 票突发异动，用户不仅能查看K线，还能即时获取大V深度分析，甚至直接下单交易。一位港股投资者 感叹："从看到康希诺生物异动7%的推送，到阅读分析并完成交易，全程不到一分钟。" 市场选择背后的理性逻辑 横向对比各专业平台：同花顺以闪电交易速度见长，Wind以机构级数据称雄，东方财富的社区生态无 人能及。但新浪财经凭借全球监控、智能工具、社交验证的三维架构，成为唯一能同时满足短线交易 者、期货套利客、价值投资者的超级入口。据统计，2025年南向资金通过新浪财经APP净流入突破6500 亿港元，其香港持牌资质与全程资产隔离托管机制，成为跨境投资者的信任基石。 8月13日，A股三大指数午后震荡，截至收盘，上证指数涨0.48%，突破去年的3674点高点，深证成指涨 1.76%，创业板指涨3.62%。盘面上，CPO概念全天大涨，光库科技20%涨停；券商板块大涨，国盛金控 涨停；光芯片、工业气体、CRO等板块 ...

Group 1 - The Shanghai Composite Index rose by 0.5% to close at 3665.92 points, while the Hang Seng Index increased by 0.25% to 24969.68 points [1] - CanSino Biologics has an AH premium of 91.3%, ranking 35th among AH shares. The A-shares closed at 82.5 yuan, down 3.06%, and the H-shares closed at 47.08 HKD, down 6.96% [1] - CanSino Biologics, founded in 2009 in China, focuses on providing innovative, high-quality, and accessible vaccines for the prevention and treatment of infectious diseases, positioning itself as a leading high-tech biopharmaceutical company [1] Group 2 - The company's mission is to provide innovative, high-quality, and accessible vaccines globally, aiming for the vision of "Innovation without end, a world without epidemics" [1] - CanSino Biologics is listed on both the Hong Kong Stock Exchange (H shares, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A shares, stock code 688185), being the first "A+H" vaccine stock since the launch of the STAR Market [1]

Core Viewpoint - The Chinese innovative pharmaceutical industry is transitioning from imitation-based innovation to original innovation, and there is a strong emphasis on expanding into emerging overseas markets to achieve high-quality development [1][2]. Group 1: Industry Insights - Since the reform of the drug review and approval system in 2015, China's innovative drugs have entered a rapid development phase [1]. - Experts at the "Future Path of Chinese New Drugs (T20+)" conference suggested that collaboration among various stakeholders is essential to accelerate the internationalization of innovative drugs [1]. - The potential market in developing countries is significant due to their large populations, and China's innovative drugs are seen as high-quality and affordable alternatives [1]. Group 2: Company Initiatives - Companies like BeiGene, China Biologic Products, and CanSino Biologics are taking proactive steps to promote their innovative drugs in developing countries, contributing to global health challenges such as infectious diseases and chronic illnesses [1]. - A new alliance called the "Emerging Market New Drug Product Export Alliance" was established to facilitate experience sharing and collaborative efforts in promoting products to more countries [2].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.69% as of August 7, 2025, with mixed performance among constituent stocks [1] - Huada Zhizao led the gains with an increase of 4.42%, while Yuyuan Pharmaceutical and others experienced declines [1][5] - The market for the Sci-Tech Innovation Medical ETF managed by Harvest saw a turnover of 27.9% and a transaction volume of 65.88 million yuan, indicating active trading [3] Group 2 - As of August 6, 2025, the Sci-Tech Innovation Medical ETF reached a new high in scale at 237 million yuan, ranking first among comparable funds [3] - The ETF saw a net inflow of 2.96 million yuan recently, with a total of 17.65 million yuan accumulated over the last five trading days [3] - The ETF's net value increased by 49.39% over the past year, with the highest monthly return recorded at 23.29% since its inception [3] Group 3 - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading stocks including United Imaging Healthcare and BeiGene [3] - Minsheng Securities believes that domestic medical insurance policy support and overseas value recognition will sustain the ongoing trend of Chinese innovative drugs [5] - China has become a core procurement area for global trading, with traditional pharmaceutical companies accelerating their innovation and international expansion [5]

Core Viewpoint - MiMedia Holdings Inc. has partnered with ADG China to enhance its business development within the smartphone OEM ecosystem in Asia, aiming to expand the distribution of its consumer cloud platform [1][3]. Company Overview - MiMedia Holdings Inc. offers a next-generation consumer AI cloud platform that secures personal media in the cloud, accessible across devices and operating systems. The platform features rich media experiences, organization tools, private sharing capabilities, and content re-engagement features, servicing millions of engaged users globally [5]. Partnership Details - ADG China has a strong track record in bridging Western technology companies with Chinese distribution channels, having signed over 75 cross-border technology deals since 2001. The firm has integrated numerous companies onto hundreds of millions of devices from leading Chinese smartphone OEMs such as Vivo, Xiaomi, and Oppo [2][4]. - The partnership is expected to accelerate MiMedia's ability to sign new OEM partners, leveraging ADG's extensive network and experience in the Chinese market [3]. Market Context - The timing of the partnership is seen as favorable, with smartphone OEMs looking for solutions like MiMedia's to capture new recurring revenue streams, reduce churn, and differentiate themselves in a competitive market [3].

承董事會命 康希諾生物股份公司 Xuefeng YU 董事長 香港，2025年8月6日 （股份代號：6185） 董事會會議通告 康 希 諾 生 物 股 份 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議將於2025年8月20日（星 期 三）舉 行，藉 以（其 中 包 括）考 慮 及 批 准 本 公 司 及 其 附 屬公司截至2025年6月30日止六個月的中期業績及其發佈，以及考慮建議派發中 期 股 息（如 有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本通告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 於本通告日期，本公司董事會包括執行董事Xuefeng YU博士、Shou Bai CHAO博 士 及王靖女士；非執行董事李志成先生；以及獨立非執行董事桂水發先生、劉建忠 先生及張耀樑先生。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年8月6日 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 132,670,900 | | 0 | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 132,670,900 | | 0 | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 (註 ...

Core Viewpoint - The article highlights the performance of the stock market on August 6, with a focus on the significant price movements of CanSino Biologics, which has a notable A/H share premium and is recognized as a leading high-tech biopharmaceutical company in China [1][3]. Group 1: Market Performance - On August 6, the Shanghai Composite Index rose by 0.45%, closing at 3633.99 points, while the Hang Seng Index increased by 0.03%, closing at 24910.63 points [1]. - CanSino's A-shares closed at 88.48 yuan, reflecting a 6.13% increase, while its H-shares closed at 52.05 HKD, showing a 9.21% rise [1]. Group 2: Company Overview - CanSino Biologics was established in 2009 in China, focusing on providing solutions for the prevention and treatment of infectious diseases globally [1]. - The company specializes in the research, production, and commercialization of innovative, high-quality, and accessible human vaccines, positioning itself as a leading high-tech biopharmaceutical enterprise [1]. - CanSino's mission is to provide innovative, high-quality, and accessible vaccines globally, aiming for the vision of "Innovation without end, a world without epidemics" [1]. - The company is listed on both the Hong Kong Stock Exchange (H-shares, stock code 6185.HK) and the Shanghai Stock Exchange's STAR Market (A-shares, stock code 688185), being the first "A+H" vaccine stock since the launch of the STAR Market [1].

格隆汇8月6日丨康希诺生物(06185.HK)宣布，董事会会议将于2025年8月20日（星期三）举行，藉以 （其中包括）考虑及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩及其发布，以及考 虑建议派发中期股息（如有）。 ...

科创板股最新收盘价较发行价平均溢价118.34%，其中，142股出现破发。 证券时报·数据宝统计显示，已上市的589只科创板股中，最新收盘价较发行价平均溢价118.34%，其 中，收盘价较发行价溢价的有446只，溢价幅度最高的是上纬新材，最新收盘价较发行价溢价 3534.29%，热景生物、百利天恒、安集科技等紧随其后，分别溢价1237.28%、1139.64%、1083.81%。 最新收盘价较发行价出现折价的有142只，也即是破发。 破发幅度最大的是万润新能，最新价较发行价折价78.81%，该股2022年9月29日上市，发行价为299.88 元，发行市盈率为75.25倍，行业平均市盈率为19.21倍，公司主要从事锂电池正极材料的研发、生产和 销售。 科创板股破发幅度排名 | 代码 | 简称 | 上市日期 | 发行价（元） | 最新收盘价（元） | 较发行价折溢价（%） | | --- | --- | --- | --- | --- | --- | | 688275 | 万润新能 | 2022.09.29 | 299.88 | 41.90 | -78.81 | | 688184 | ST帕瓦 | 2022.09 ...